CPIX · Insider Trading
Cumberland Pharmaceuticals Inc
Every open-market purchase and sale reported by CPIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | Joseph C Galante | Director | A | +1,800 | +$5.04K |
| 2026-03-20 | John M. Hamm | VP Chief Financial Officer | A | +3,000 deriv. | — |
| 2026-03-20 | Chris T. Bitterman | Vice Pres Sales & Marketing | A | +3,000 deriv. | — |
| 2026-03-20 | Todd M. Anthony | Vice Pres Organizational Dev | A | +3,000 deriv. | — |
| 2026-03-20 | James Jones | Director | A | +1,800 | +$5.04K |
| 2026-03-20 | Martin S Brown JR | Director | A | +1,800 | +$5.04K |
| 2026-03-20 | James L Herman | VP and Chief Compliance Office | A | +2,500 deriv. | — |
| 2026-03-20 | A J Kazimi | Chairman and CEO | A | +100,000 deriv. | — |
| 2026-03-20 | Caroline Young | Director | A | +1,800 | +$5.04K |
| 2026-03-20 | Kenneth Krogulski | Director | A | +5,800 | +$16.24K |
| 2026-03-18 | A J Kazimi | Chairman and CEO | F | −5,845 | −$17.89K |
| 2026-01-06 | Kenneth Krogulski | Director | L | +1,916 | +$5.65K |
| 2026-01-06 | James Jones | Director | L | +270 | +$799 |
| 2026-01-06 | A J Kazimi | Chairman and CEO | L | +270 | +$799 |
| 2026-01-06 | Caroline Young | Director | L | +66 | +$202 |
| 2025-12-01 | James Jones | Director | L | +302 | +$664 |
| 2025-12-01 | A J Kazimi | Chairman and CEO | L | +302 | +$664 |
| 2025-12-01 | Caroline Young | Director | L | +75 | +$170 |
| 2025-12-01 | Kenneth Krogulski | Director | L | +2,027 | +$4.42K |
| 2025-11-03 | A J Kazimi | Chairman and CEO | L | +299 | +$1.02K |
| 2025-11-03 | Caroline Young | Director | L | +138 | +$472 |
| 2025-11-03 | Kenneth Krogulski | Director | L | +1,564 | +$5.34K |
| 2025-11-03 | James Jones | Director | L | +299 | +$1.02K |
| 2025-10-03 | Caroline Young | Director | L | +88 | +$295 |
| 2025-10-03 | Kenneth Krogulski | Director | L | +1,314 | +$4.41K |
| 2025-10-03 | A J Kazimi | Chairman and CEO | L | +254 | +$853 |
| 2025-10-03 | James Jones | Director | L | +254 | +$853 |
| 2025-09-12 | James Jones | Director | Buy | +262 | +$862 |
| 2025-09-12 | A J Kazimi | Chairman and CEO | Buy | +262 | +$862 |
| 2025-09-12 | Kenneth Krogulski | Director | Buy | +1,372 | +$4.52K |
| 2025-09-12 | Caroline Young | Director | Buy | +121 | +$398 |
| 2025-08-11 | Kenneth Krogulski | Director | Buy | +1,712 | +$5.87K |
| 2025-08-11 | Caroline Young | Director | Buy | +168 | +$578 |
| 2025-08-11 | A J Kazimi | Chairman and CEO | Buy | +340 | +$1.17K |
| 2025-08-11 | James Jones | Director | Buy | +340 | +$1.17K |
| 2025-07-11 | James Jones | Director | Buy | +168 | +$807 |
| 2025-07-11 | A J Kazimi | Chairman and CEO | Buy | +168 | +$807 |
| 2025-07-11 | Kenneth Krogulski | Director | Buy | +935 | +$4.51K |
| 2025-07-11 | Caroline Young | Director | Buy | +84 | +$404 |
| 2025-06-06 | James Jones | Director | Buy | +168 | +$858 |
| 2025-06-06 | A J Kazimi | Chairman and CEO | Buy | +168 | +$858 |
| 2025-06-06 | Caroline Young | Director | Buy | +84 | +$429 |
| 2025-06-06 | Kenneth Krogulski | Director | Buy | +945 | +$4.82K |
| 2025-05-09 | A J Kazimi | Chairman and CEO | Buy | +186 | +$833 |
| 2025-05-09 | James Jones | Director | Buy | +186 | +$833 |
| 2025-05-09 | Caroline Young | Director | Buy | +93 | +$417 |
| 2025-05-09 | Kenneth Krogulski | Director | Buy | +1,035 | +$4.64K |
| 2025-04-04 | A J Kazimi | Chairman and CEO | Buy | +168 | +$881 |
| 2025-04-04 | Caroline Young | Director | Buy | +74 | +$384 |
| 2025-04-04 | Kenneth Krogulski | Director | Buy | +875 | +$4.55K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| A J Kazimi | Chairman and CEO | 5,695,310 | $25.29M |
| Kenneth Krogulski | Director | 302,338 | $1.34M |
| Joseph C Galante | Director | 63,656 | $282.63K |
| James Jones | Director | 46,863 | $208.07K |
| James L Herman | VP and Chief Compliance Office | 38,255 | $169.85K |
| Caroline Young | Director | 35,109 | $155.88K |
| John M. Hamm | VP Chief Financial Officer | 20,073 | $89.12K |
| Todd M. Anthony | Vice Pres Organizational Dev | 16,328 | $72.50K |
| Martin S Brown JR | Director | 10,300 | $45.73K |
| Chris T. Bitterman | Vice Pres Sales & Marketing | 4,683 | $20.79K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CPIX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.